Department of Biomedical and Chemical Engineering, Syracuse University, Syracuse, New York, USA.
Syracuse Biomaterials Institute, Syracuse University, Syracuse, New York, USA.
Appl Environ Microbiol. 2020 Dec 17;87(1). doi: 10.1128/AEM.02083-20.
Bacteria can survive antibiotic treatment both by acquiring antibiotic resistance genes and through mechanisms of tolerance that are based on phenotypic changes and the formation of metabolically inactive cells. Here, we report an strain ( UM001B) that was isolated from a cystic fibrosis patient and had no increase in resistance but extremely high-level tolerance to ampicillin, vancomycin, and tetracycline. Specifically, the percentages of cells that survived 3.5-h antibiotic treatment (at 100 μg · ml) were 25.4% ± 4.3% and 51.9% ± 4.0% for ampicillin and tetracycline, respectively; vancomycin did not exhibit any significant killing. Consistent with the changes in antibiotic susceptibility, UM001B was found to have reduced penetration of ampicillin and vancomycin and accumulation of tetracycline compared to the reference strain ATCC 29212. Based on whole-genome sequencing, four amino acid substitutions were identified in one of the tetracycline efflux pump repressors (TetRs), compared to ATCC 29212. Results of molecular simulations and experimental assays revealed that these mutations could lead to higher levels of tetracycline efflux activity. Consistently, replicating these mutations in MG1655 increased its tolerance to tetracycline. Overall, these findings provide new insights into the development of multidrug tolerance in , which can facilitate future studies to better control enterococcal infections. represents a major group of pathogens causing nosocomial infections that are resistant to multiple classes of antibiotics. An important challenge associated with infection is the emergence of multidrug-tolerant strains, which have normal MICs but do not respond to antibiotic treatment. Here, we report a strain of that was isolated from a cystic fibrosis patient and demonstrated high-level tolerance to ampicillin, vancomycin, and tetracycline. Whole-genome sequencing revealed critical substitutions in one of the tetracycline efflux pump repressors that are consistent with the increased tolerance of UM001B to tetracycline. These findings provide new information about bacterial antibiotic tolerance and may help develop more effective therapeutics.
细菌可以通过获得抗生素耐药基因和通过基于表型变化和代谢不活跃细胞形成的耐受机制来对抗抗生素治疗。在这里,我们报告了一株从囊性纤维化患者中分离出来的 菌株(UM001B),它没有增加耐药性,但对氨苄西林、万古霉素和四环素具有极高水平的耐受性。具体而言,在 3.5 小时的抗生素治疗(100μg·ml)中,存活的细胞百分比分别为 25.4%±4.3%和 51.9%±4.0%,氨苄西林和四环素分别为 51.9%±4.0%;万古霉素没有表现出任何显著的杀伤作用。与抗生素敏感性的变化一致,与参考菌株 ATCC 29212 相比,UM001B 发现氨苄西林和万古霉素的穿透性降低,四环素的积累增加。基于全基因组测序,与 ATCC 29212 相比,在一个四环素外排泵抑制剂(TetRs)中发现了四个氨基酸取代。分子模拟和实验检测结果表明,这些突变可能导致四环素外排活性水平升高。一致地,在 MG1655 中复制这些突变增加了其对四环素的耐受性。总的来说,这些发现为 多药耐受的发展提供了新的见解,这可以促进未来的研究更好地控制肠球菌感染。 是引起医院感染的主要病原体之一,对多种类别的抗生素具有耐药性。与 感染相关的一个重要挑战是出现多药耐药菌株,这些菌株的 MIC 正常,但对抗生素治疗没有反应。在这里,我们报告了一株从囊性纤维化患者中分离出来的 菌株,该菌株对氨苄西林、万古霉素和四环素表现出高水平的耐受性。全基因组测序揭示了一个四环素外排泵抑制剂中的关键取代,与 UM001B 对四环素的耐受性增加一致。这些发现提供了关于细菌对抗生素耐受性的新信息,并可能有助于开发更有效的治疗方法。